Home NDC 66993-397 Solifenacin Succinate
Product NDC 66993-397
11-digit product format 669930397
Labeler code 66993
Product ID 66993-397_e22e54f0-125d-495d-8e4d-1a6c63f275bf
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name solifenacin succinate
Dosage form TABLET, FILM COATED
Route ORAL
Labeler Prasco
Application NDA021518
Marketing category NDA AUTHORIZED GENERIC
Marketing start 2019-05-20
Marketing end 0000-00-00
Substance SOLIFENACIN SUCCINATE
Active strength 5 mg/1
Pharmacologic classes Cholinergic Muscarinic Antagonist [EPC],Cholinergic Muscarinic Antagonists [MoA]
NDC exclude flag No
Listing certified through 2020-12-31
Current FDA listing Historical FDA.report record
Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 36 matching rows.
View current auxiliary records. · View the auxiliary file history.
Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N021518-001 VESICARE SOLIFENACIN SUCCINATE 5MG TABLET / ORAL RLD 2004-11-19 N021518-002 VESICARE SOLIFENACIN SUCCINATE 10MG TABLET / ORAL RLD 2004-11-19
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 86 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N021518-001 VESICARE 5MG TABLET / ORAL RLD 2004-11-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N021518-002 VESICARE 10MG TABLET / ORAL RLD 2004-11-19 84e616aacf4f…2026-08-18 06:07:40 2026-07 N021518-001 VESICARE 5MG TABLET / ORAL RLD 2004-11-19 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N021518-002 VESICARE 10MG TABLET / ORAL RLD 2004-11-19 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N021518-001 VESICARE 5MG TABLET / ORAL RLD 2004-11-19 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N021518-002 VESICARE 10MG TABLET / ORAL RLD 2004-11-19 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N021518-001 VESICARE 5MG TABLET / ORAL AB RLD 2004-11-19 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N021518-002 VESICARE 10MG TABLET / ORAL AB RLD, RS 2004-11-19 74a2ff9319b5…
Observed Orange Book normalized TE history# Normalized TE history page 2 of 2 · 78 observed states.
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2019-12-13 00:20 UTC 2019-12 N021518-001 6017927*PED 2019-05-19 Pediatric extension 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N021518-002 6017927*PED 2019-05-19 Pediatric extension 74a2ff9319b5…2019-12-14 00:12 UTC 2019-12 N021518-001 6017927*PED 2019-05-19 Pediatric extension 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N021518-002 6017927*PED 2019-05-19 Pediatric extension 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N021518-001 6017927*PED 2019-05-19 Pediatric extension b00525d2431f…2019-09-15 20:21 UTC 2019-09 N021518-002 6017927*PED 2019-05-19 Pediatric extension b00525d2431f…2019-07-19 19:46 UTC 2019-07 N021518-001 6017927*PED 2019-05-19 Pediatric extension ea99ee380514…2019-07-19 19:46 UTC 2019-07 N021518-002 6017927*PED 2019-05-19 Pediatric extension ea99ee380514…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.